- Home
- SMTK vs BCDA Comparison
SMTK vs BCDA Comparison
Compare SMTK & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTK
- BCDA
- Stock Information
- Founded
- SMTK 2009
- BCDA N/A
- Country
- SMTK United Kingdom
- BCDA United States
- Employees
- SMTK N/A
- BCDA N/A
- Industry
- SMTK
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- SMTK
- BCDA Health Care
- Exchange
- SMTK NYSE
- BCDA Nasdaq
- Market Cap
- SMTK 13.3M
- BCDA 11.5M
- IPO Year
- SMTK N/A
- BCDA N/A
- Fundamental
- Price
- SMTK $2.61
- BCDA $2.31
- Analyst Decision
- SMTK
- BCDA Strong Buy
- Analyst Count
- SMTK 0
- BCDA 1
- Target Price
- SMTK N/A
- BCDA $25.00
- AVG Volume (30 Days)
- SMTK 14.6K
- BCDA 67.3K
- Earning Date
- SMTK 03-04-2025
- BCDA 03-26-2025
- Dividend Yield
- SMTK N/A
- BCDA N/A
- EPS Growth
- SMTK N/A
- BCDA N/A
- EPS
- SMTK N/A
- BCDA N/A
- Revenue
- SMTK $40,000.00
- BCDA $71,000.00
- Revenue This Year
- SMTK N/A
- BCDA N/A
- Revenue Next Year
- SMTK N/A
- BCDA N/A
- P/E Ratio
- SMTK N/A
- BCDA N/A
- Revenue Growth
- SMTK 471.43
- BCDA N/A
- 52 Week Low
- SMTK $2.01
- BCDA $1.63
- 52 Week High
- SMTK $13.00
- BCDA $8.85
- Technical
- Relative Strength Index (RSI)
- SMTK N/A
- BCDA 45.73
- Support Level
- SMTK N/A
- BCDA $2.27
- Resistance Level
- SMTK N/A
- BCDA $2.95
- Average True Range (ATR)
- SMTK 0.00
- BCDA 0.26
- MACD
- SMTK 0.00
- BCDA -0.02
- Stochastic Oscillator
- SMTK 0.00
- BCDA 22.89
About SMTK SMARTKEM INC
SmartKem Inc focuses on the design, development, industrialization, and technology transfer of low-temperature, solution-deposited organic semiconductors for transistor backplanes. The company's semiconductor platform can be used in a number of applications including mini-LED displays, AMOLED displays, fingerprint sensors, and logic circuits. The company derives revenue from the sale of TRUFLEX inks and demonstration products.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).